Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Database | Synapse
March 3, 2026Open Access
Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Database
Key Points
Simultaneous resection of pancreatic cancer and liver metastases indicates a potential survival benefit.
Data analysis across the National Cancer Database supports feasibility and safety of this combined surgical approach.
This approach may enable better treatment outcomes, but careful patient selection is crucial.
Abstract
Neoadjuvant therapy followed by simultaneous liver and pancreas resection for metastatic PDAC is safe and feasible, and it may provide a survival benefit in carefully selected patient populations.